Supplementary Table 4.
Proportion of patientswith anti-S trimer <100 BAU/mL, % (n/N) | Ratio of relative risk | |||
---|---|---|---|---|
CNI and other | Age >65 y | eGFR <45 mL/min | 100 (7/7) | 6.25 |
eGFR ≥45 mL/min | 100 (6/6) | 6.25 | ||
Age ≤65 y | eGFR <45 mL/min | 87 (13/15) | 5.44 | |
eGFR ≥45 mL/min | 45 (22/49) | 2.81 | ||
CNI mono | Age ≤65 y | eGFR ≥45 mL/min | 16 (3/19) | 1 |
eGFR <45 mL/min | 75 (3/4) | 4.69 | ||
Age >65 y | eGFR ≥45 mL/min | 1/1 | ||
eGFR <45 mL/min | 0 |
Anti-S trimer, Anti-SARS-CoV-2 antibodies in DiaSorin LIAISON immunoassay; BAU, binding antibody units; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; LT, liver transplant.
The table illustrates the risk of vaccination failure, defined by anti-S trimer <100 BAU/mL, in LT recipients with a combination of several risk factors. The percentage of patients with vaccination failure in the respective patient group is indicated. Also, the relative risk compared with LT patients with optimal prognostic parameters (ie, CNI monotherapy plus ≤65 years plus eGFR ≥45 mL/min) is given.
Colors visualize the relative risk: green 1.0, yellow >1 and ≤4, orange >4 and ≤6, red >6, grey: not available due to low number of subjects)